Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

A DAD died after taking a weight loss jab for just a few weeks. Tim Ramsay, from South Australia, wanted to shed some pounds so he could confidently walk his daughter down the aisle. The ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Dutch pharmacies distributed prescriptions for €31 million-worth of weight loss drugs such as Ozempic, Saxenda en Wegovy in ...

A dad died just days after using a weight-loss jab so he could ‘confidently walk his daughter down the aisle’, and now his family are demanding answers. Back in 2022, Tim Ramsay decided he wanted to ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...